PAX5::AUTS2 childhood B-ALL: a relapse-prone genetic subtype with frequent central nervous system involvement and a poor outcome
Status In-Process Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články
Grantová podpora
825749
EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
IG-2023 n. 29191
Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
POIR.04.04.00-00-16ED/18-00
Fundacja na rzecz Nauki Polskiej (Foundation for Polish Science)
DKS 2021.14
Deutsche Kinderkrebsstiftung (German Childhood Cancer Foundation)
1193718-BRA-HFSTCAPES-P
Alexander von Humboldt-Stiftung (Alexander von Humboldt Foundation)
FAPERJ (E_13/2023)
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (Carlos Chagas Filho Foundation for Research Support in the State of Rio de Janeiro)
FAPERJ (E-26/201.113/2021)
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (Carlos Chagas Filho Foundation for Research Support in the State of Rio de Janeiro)
PubMed
39702796
PubMed Central
PMC11794147
DOI
10.1038/s41375-024-02502-5
PII: 10.1038/s41375-024-02502-5
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
[Image: see text]
Department of Genetic Predisposition to Cancer Medical University of Łódź Łódź Poland
Department of Genetics University Hospital Robert Debré Paris France
Department of Human Genetics Hannover Medical School Hannover Germany
Department of Laboratory Haematology and Cytogenetics Tata Medical Centre Kolkata India
Department of Pediatrics Oncology and Hematology Medical University of Łódź Łódź Poland
Dutch Childhood Oncology Group Utrecht The Netherlands
INSERM UMR_S1131 Institut de Recherche Saint Louis Université Paris Cité Paris France
Labdia Labordiagnostik Vienna Austria
Leukemia DataLab Instituto Nacional de Câncer INCA Rio de Janeiro Brazil
Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands
School of Medicine and Surgery University of Milano Bicocca Milan Italy
St Anna Children's Cancer Research Institute Vienna Austria
Tettamanti Center Fondazione IRCCS San Gerardo dei Tintori Monza Italy
Zobrazit více v PubMed
Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51:296–307. PubMed PMC
Nebral K, Denk D, Attarbaschi A, Konig M, Mann G, Haas OA, et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia. 2009;23:134–43. PubMed
Fazio G, Bresolin S, Silvestri D, Quadri M, Saitta C, Vendramini E, et al. PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120. EBioMedicine. 2022;83:104224. PubMed PMC
Schwab C, Cranston RE, Ryan SL, Butler E, Winterman E, Hawking Z, et al. Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial. Leukemia. 2023;37:529–38. PubMed PMC
Luhmann JL, Zimmermann M, Hofmann W, Bergmann AK, Moricke A, Cario G, et al. Deciphering the molecular complexity of the IKZF1(plus) genomic profile using optical genome mapping. Haematologica. 2024;109:1582–7. PubMed PMC
Fazio G, Bardini M, De Lorenzo P, Grioni A, Quadri M, Pedace L, et al. Recurrent genetic fusions redefine MLL germline acute lymphoblastic leukemia in infants. Blood. 2021;137:1980–4. PubMed
Popov A, Tsaur G, Permikin Z, Henze G, Verzhbitskaya T, Plekhanova O, et al. Genetic characteristics and treatment outcome in infants with KMT2A germline B-cell precursor acute lymphoblastic leukemia: results of MLL-Baby protocol. Pediatr Blood Cancer. 2023;70:e30204. PubMed
Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, et al. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood Cancer Discov. 2021;2:326–37. PubMed PMC
Li Z, Lee SHR, Chin WHN, Lu Y, Jiang N, Lim EH, et al. Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia. Blood Adv. 2021;5:5226–38. PubMed PMC
Stanulla M, Dagdan E, Zaliova M, Moricke A, Palmi C, Cazzaniga G, et al. IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2018;36:1240–9. PubMed
Schwab C, Nebral K, Chilton L, Leschi C, Waanders E, Boer JM, et al. Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia? Blood Adv. 2017;1:1473–7. PubMed PMC
Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009;27:5168–74. PubMed
Boer JM, Valsecchi MG, Hormann FM, Antic Z, Zaliova M, Schwab C, et al. Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. Leukemia. 2021;35:2978–82. PubMed PMC
van der Sluis IM, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N Engl J Med. 2023;388:1572–81. PubMed
Lyons KU, Gore L. Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia. Haematologica. 2024;109:1668–76. PubMed PMC
